Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Andreas Huennemeyer
Observed names:
A HUENNEMEYER,
A. Huennemeyer
Institution:
Boehringer Ingelheim (Germany)
Observed institutions:
Boehringer Ingelheim (Germany),
Altana (Netherlands)
OpenAlex ID:
A5068537404
Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity
2006
·
A WESTLINDJOHNSSON
, R HERMANN
, et al.
·
Clinical Pharmacology & Therapeutics
·
128
Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N‐oxide in healthy subjects
2009
·
Nassr Nassr
, Andreas Huennemeyer
, et al.
·
British Journal of Clinical Pharmacology
·
48
PDF
Effect of Single and Repeated Doses of Ketoconazole on the Pharmacokinetics of Roflumilast and Roflumilast N‐Oxide
2008
·
Gezim Lahu
, Andreas Huennemeyer
, et al.
·
The Journal of Clinical Pharmacology
·
35
Effect of Fluvoxamine on the Pharmacokinetics of Roflumilast and??Roflumilast??N-Oxide
2007
·
Oliver von Richter
, Gezim Lahu
, et al.
·
Clinical Pharmacokinetics
·
35
Effect of repeated dose of erythromycin on the pharmacokinetics of roflumilast and roflumilast N-oxide
2009
·
G. Lahu
, A. Huennemeyer
, et al.
·
International Journal of Clinical Pharmacology and Therapeutics
·
28
Effect of Steady-State Enoxacin on Single-Dose Pharmacokinetics of Roflumilast and Roflumilast N-Oxide
2010
·
Gezim Lahu
, Nassr Nassr
, et al.
·
The Journal of Clinical Pharmacology
·
23
Pharmacokinetics and safety of Roflumilast, a once-daily, oral, selective PDE4 inhibitor, and its active metabolite Roflumilast N-oxide in healthy subjects*1
2004
·
A HUENNEMEYER
·
Journal of Allergy and Clinical Immunology
·
15
Midazolam microdosing applied in early clinical development for drug–drug interaction assessment
2020
·
Sabrina T. Wiebe
, Andreas Huennemeyer
, et al.
·
British Journal of Clinical Pharmacology
·
12
PDF
Chronopharmacology of Roflumilast: a Comparative Pharmacokinetic Study of Morning Versus Evening Administration in Healthy Adults
2010
·
Thomas D. Bethke
, Andreas Huennemeyer
, et al.
·
Chronobiology International
·
6
Supra-therapeutic doses of roflumilast have no effect on cardiac repolarization in healthy subjects
2011
·
Andreas Huennemeyer
, Nassr Nassr
, et al.
·
Expert Opinion on Drug Safety
·
3
Safety, tolerability and pharmacokinetics of single rising doses of BI 1569912 in healthy males – a Phase I study
2022
·
M. Desch
, A. Huennemeyer
, et al.
·
Neuroscience Applied
·
1
PDF
Roflumilast Shows No Pharmacokinetic Interaction with Warfarin in Healthy Subjects
2004
·
Andreas Huennemeyer
, K. Zech
, et al.
·
CHEST Journal
·
1
Oral, Once-Daily Roflumilast and Its Active N-oxide Metabolite Exhibit Dose-Proportional Pharmacokinetics Between 250μg and 500μg
2004
·
Andreas Huennemeyer
, K. Zech
, et al.
·
CHEST Journal
·
1
Pharmacokinetics of the selective PDE4 inhibitor Roflumilast and its active metabolite Roflumilast N-oxide are not affected by concomitant budesonide, salbutamol, or erythromycin
2004
·
B. Hauns
, A. Huennemeyer
, et al.
·
Journal of Allergy and Clinical Immunology
·
1
PDF
P712. Safety, Tolerability, and Pharmacokinetics of Single Rising Doses of Bi 1569912 in Healthy Males: A Phase I Study
2022
·
Michael Desch
, Andreas Huennemeyer
, et al.
·
Biological Psychiatry
Show more works
View as search
Works count:
15
Citation count:
337
H-index:
8
I10-index:
8
Year
Topic
Type
